Tango Therapeutics, Inc. (TNGX)
NASDAQ:TNGX
Want to see TNGX full AI Analyst Report?
TNGX Stock Chart & Stats
$26.64
-$0.22(-6.34%)
At close: 4:00 PM EST
$26.64
-$0.22(-6.34%)
Day’s Range― - ―
52-Week Range$4.32 - $32.79
Previous CloseN/A
Volume187.94K
Average Volume (3M)3.57M
Market Cap
$4.15B
Enterprise Value$2.43B
Total Cash (Recent Filing)$379.84M
Total Debt (Recent Filing)$32.79M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 12, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding144,647,980
10 Day Avg. Volume4,547,818
30 Day Avg. Volume3,570,935
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.97
Price to Sales (P/S)16.50
P/FCF Ratio-7.36
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue42.61
Enterprise Value/Gross Profit43.81
Enterprise Value/Ebitda-21.44
Forecast
1Y Price Target
$38.64Price Target Upside45.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$6.06M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable EquityVery low leverage and meaningful equity provide durable financial flexibility for a clinical-stage biotech. Modest debt reduces interest and covenant risk, enabling the company to fund multi-year pivotal trials, pursue partnerships, and withstand R&D setbacks without immediate solvency pressure.
Compelling Vopimetostat Combo Clinical DataRobust early combo efficacy and tolerability that management is advancing to Phase 3 is a structural positive: if replicated in randomized pivotal trials, this creates a clear regulatory path, first-in-class positioning in MTAP-deleted pancreatic cancer, and durable commercial and partnership optionality.
Very High Gross MarginsExtremely high gross margins reflect favorable unit economics typical of small-molecule oncology assets. If a product reaches commercialization, these economics support high long-term operating leverage, attractive royalty/partner economics, and the ability to reinvest revenue into R&D or margin expansion.
Bears Say
Large And Persistent Cash BurnSustained, sizable negative operating and free cash flows are a fundamental risk for a development-stage biotech. Continued burn will steadily deplete resources, increasing dependency on external capital and potentially forcing program prioritization or slowed development if markets tighten.
Substantial Operating Losses And Softening RevenueLarge operating losses and declining trailing revenue highlight weak near-term profitability and limited recurring commercial receipts. This structural earnings shortfall necessitates ongoing funding, constrains reinvestment flexibility, and raises execution risk ahead of any potential product revenues.
Reliance On External Equity FinancingFrequent or large equity raises signal structural funding dependence to advance late-stage programs. Equity issuance can dilute existing holders and ties strategic pacing to capital markets; this reliance reduces margin of error for clinical timelines and makes execution contingent on favorable market access.
Tango Therapeutics News
TNGX FAQ
What was Tango Therapeutics, Inc.’s price range in the past 12 months?
Tango Therapeutics, Inc. lowest stock price was $4.32 and its highest was $32.79 in the past 12 months.
What is Tango Therapeutics, Inc.’s market cap?
Tango Therapeutics, Inc.’s market cap is $4.15B.
When is Tango Therapeutics, Inc.’s upcoming earnings report date?
Tango Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 62 days.
How were Tango Therapeutics, Inc.’s earnings last quarter?
Tango Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.314 by -$0.006.
Is Tango Therapeutics, Inc. overvalued?
According to Wall Street analysts Tango Therapeutics, Inc.’s price is currently Undervalued.
Does Tango Therapeutics, Inc. pay dividends?
Tango Therapeutics, Inc. does not currently pay dividends.
What is Tango Therapeutics, Inc.’s EPS estimate?
Tango Therapeutics, Inc.’s EPS estimate is -0.32.
How many shares outstanding does Tango Therapeutics, Inc. have?
Tango Therapeutics, Inc. has 144,647,980 shares outstanding.
What happened to Tango Therapeutics, Inc.’s price movement after its last earnings report?
Tango Therapeutics, Inc. reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.314. Following the earnings report the stock price went down -2.509%.
Which hedge fund is a major shareholder of Tango Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tango Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.64 (45.03% Upside)
$38.64 (45.03% Upside)
Blogger Sentiment
Bearish
TNGX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $241.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 16.0%
Last 30 Days ▲ 15.6%
Last 30 Days ▲ 15.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
658.65%
12-Months-Change
Fundamentals
Return on Equity
-41.54%
Trailing 12-Months
Asset Growth
58.87%
Trailing 12-Months
Company Description
Tango Therapeutics, Inc.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
TNGX Stock 12 Month Forecast
Average Price Target
$38.64
▲(45.03% Upside)
Technical Analysis
Oruka Therapeutics
―
Immatics
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
10.98% Insiders
8.10% Mutual Funds
10.88% Other Institutional Investors
58.97% Public Companies and Individual Investors